Ninety-two women in preterm labor were randomly assigned to either terbutaline or ethanol. In women with intact membranes, terbutaline was significantly more effective than ethanol in preventing progressive cervical dilation during the first 36 hours of treatment while betamethasone was given to the mother. Additionally, pregnancy was maintained significantly longer in women with intact membranes who were treated with terbutaline (15 +/- 4 days) rather than with ethanol (10 +/- 3 days). However, only 18% of women in each treatment group maintained their pregnancy beyond 36 weeks' gestation. In women with ruptured membranes and cervical dilation less than 4 cm, terbutaline was significantly better than ethanol in maintaining pregnancy for a minimum of 36 hours. Serious maternal side effects were not observed with terbutaline or ethanol, although a majority of women also received betamethasone. Neither drug caused serious adverse neonatal effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9378(16)32334-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.
Adv Ther
January 2023
Respiratory Medical Emerging Markets, GSK, Panama City, Panama.
Article Synopsis
- SABA reliever overuse in asthma is common, and this study analyzes the safety and tolerability of SABA monotherapy compared to inhaled corticosteroids (ICS) using systematic literature review and meta-analysis of randomized controlled trials (RCTs).
- The study reviewed 42 studies but included only 24 RCTs in the meta-analysis, finding low rates of serious adverse events (SAEs) and discontinuations due to adverse events (DAEs) in both SABA and ICS groups.
- Results showed that while DAEs were reported more often in SABA groups, the overall risk of SAEs and mortality was similar between SABA and ICS treatments, indicating that SABA monotherapy, when used appropriately
Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.
J Allergy Clin Immunol Pract
August 2021
Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Background: Medication adherence is challenging for adolescents. In mild asthma, as-needed budesonide-formoterol (BUD-FORM) reduces severe exacerbations compared with as-needed short-acting beta-agonists, similar to the reduction with maintenance budesonide.
Objective: This post hoc pooled analysis of Symbicort Given as-needed in Mild Asthma (SYGMA) 1 and 2 assessed the efficacy and safety of as-needed BUD-FORM in adolescents.
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies.
Drug Saf
April 2021
Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Introduction: Budesonide-formoterol taken as needed is an emerging treatment for mild asthma.
Objective: We used data from the SYGMA studies to assess the safety of As-needed budesonide-formoterol compared with As-needed terbutaline and compared with maintenance budesonide.
Methods: SYGMA 1 and 2 were 52-week, double-blind, parallel-group studies in patients aged ≥ 12 years with physician-assessed mild asthma.
Self-titration of inhaled corticosteroid and β-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial.
Eur Respir J
October 2020
Medical Research Institute of New Zealand, Wellington, New Zealand.
Introduction: In mild asthma, as-needed budesonide-formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β-agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β-agonist use in PRACTICAL, a randomised controlled trial.
Methods: Participants were randomised 1:1 to as-needed budesonide-formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks.
Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial.
Eur Respir J
April 2020
Medical Research Institute of New Zealand, Wellington, New Zealand.
Symptom-driven low-dose inhaled corticosteroid-formoterol is safe and effective in mild asthma and has been recommended as one of the preferred treatment regimens at steps 1 and 2 in the 2019 update of the Global Initiative for Asthma. However, there are no data on patient preferences for this regimen.A subgroup of participants in the PRACTICAL study (ACTRN12616000377437), a randomised controlled trial comparing symptom-driven budesonide-formoterol with maintenance budesonide plus as-needed terbutaline completed a survey on treatment preferences, satisfaction, beliefs and experience at their final study visit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!